Stock MIRAGEN THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Miragen Therapeutics Inc Nasdaq

Equities

US8266402036

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Miragen Therapeutics Inc
06-11 Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
06-11 Sector Update: Health Care MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
BU
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
AQ
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
BU
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PR
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BU
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
AQ
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
BU
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. Stock
  5. News Miragen Therapeutics Inc
  6. Press Releases